title: Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance.
abstract: The frequent lipoprotein lipase S447X variant (LPLS447X) is firmly associated with a lower incidence of cardiovascular disease, the mechanisms for which remain to be established. To further unravel these beneficial effects, we studied the consequences of LPLS447X heterozygosity on LPL mass and activity, as well as on the postprandial lipoprotein profile. Fifteen male heterozygous LPLS447X carriers and 15 matched control subjects received an oral fat load (30 g/m(2)). Lipid parameters were evaluated at baseline and 2, 3, 4, and 6 hours after fat loading. LPL concentration and activity were analyzed, and endothelial function was evaluated noninvasively as flow-mediated dilation of the brachial artery. Although baseline apoprotein B-48 (apoB48) levels were similar, the rise in apoB48 was attenuated in LPLS447X carriers with 25% lower peak values compared with controls (P=.04). In conjunction, LPLS447X carriers were characterized by a 2.4-fold increase in pre-heparin LPL mass (P<.0001). The decrease in postprandial flow-mediated dilation was comparable in both groups. LPLS447X carriers exhibit enhanced apoB48 clearance with concomitant increase in pre-heparin LPL mass, without changes in LPL activity. This combination might suggest a role for increased ligand action of LPL in LPLS447X carriers contributing to the cardiovascular protection in carriers of this mutation.
authors.affiliation: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
authors.forename: Melchior C
authors.initials: MC
authors.lastname: Nierman
authors.forename: Jaap
authors.initials: J
authors.lastname: Rip
authors.forename: Jan-Albert
authors.initials: JA
authors.lastname: Kuivenhoven
authors.forename: Daniel H
authors.initials: DH
authors.lastname: van Raalte
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Hutten
authors.forename: Naohiko
authors.initials: N
authors.lastname: Sakai
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
authors.forename: Erik S G
authors.initials: ES
authors.lastname: Stroes
mesh_terms: D000328:Adult; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000235:genetics* / Q000378:metabolism*; D004041:Dietary Fats / Q000097:blood / Q000493:pharmacokinetics; D004730:Endothelium, Vascular / Q000502:physiology; D014644:Genetic Variation; D006579:Heterozygote; D006801:Humans; D008024:Ligands; D008071:Lipoprotein Lipase / Q000235:genetics* / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D014280:Triglycerides / Q000097:blood; D014664:Vasodilation
chemical_list: D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; D004041:Dietary Fats; D008024:Ligands; D008074:Lipoproteins; D014280:Triglycerides; D008071:Lipoprotein Lipase